Biocon Biologics  /  Stories  /  Biocon Biologics’ 4th Biosimilar product Hulio® (bAdalimumab) launched in the U.S.

Biocon Biologics’ 4th Biosimilar product Hulio® (bAdalimumab) launched in the U.S.

With Hulio, Biocon Biologics has entered the Immunology segment

Biocon Biologics has launched HULIO®, a biosimilar to Humira® (adalimumab) in the U.S. after five years of experience in Europe and two years in Canada. bAdalimumab is Biocon Biologics’ fourth biosimilar in the U.S, after bTrastuzumab, bPegfilgrastim and bGlargine. The HULIO® launch builds on our strong presence in oncology and diabetes, and re-affirms our commitment to enabling affordable access to biologics for patients across the world.

The recent acquisition of Viatris’ global biosimilars business positions Biocon Biologics as a unique fully integrated global biologics company. It takes us closer to patients across the world, and enables us to make affordable therapies for diabetes, cancer, autoimmune diseases accessible to millions across the globe. With HULIO® available in the U.S., we have taken a huge step forward in our mission to deliver inclusive and affordable healthcare solutions.

HULIO® is a unique, patient-friendly, prefilled pen, which is designed for a seamless experience. With its simple and intuitive design, the 2-click HULIO® requires no buttons to push — patients simply remove the cap and press the device against their skin to trigger their injection.

HULIO® has undergone a rigorous review process to gain approval from U.S. FDA. It is citrate-free and does not contain natural rubber latex, which helps reduce the risk of hypersensitivity reactions in patients.

Our bAdalimumab has been serving patients globally for the last 5 years. In addition to providing HULIO®, Biocon Biologics also offers HULIO360, a comprehensive patient support program, in the U.S. This program includes a range of services such as prior authorization support, copay assistance, a bridge program, and at-home nurse support. To provide broad access for patients, Biocon Biologics is offering two options to health plans and pharmacy benefit managers.

To learn more about HULIO360 and how it can benefit patients, please visit

We want to establish HULIO® as a biosimilar of choice for patients in the U.S., that helps transform their lives with 2 easy clicks.

“Biocon Biologics is pleased to make HULIO®, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases. There are no buttons to push. Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don’t have to miss a beat with HULIO®; they simply, ‘Click, Click, Go,’”

Mathew Erick
Chief Commercial Officer of Advanced Markets
Biocon Biologics Ltd.